AB&B BIO-TECH-B (02627) has recently announced multiple breakthrough developments in its corporate innovation efforts. The clinical trial application for its independently developed Class 1 new drug, an mpox mRNA vaccine, has been accepted for review by the Center for Drug Evaluation of China's National Medical Products Administration. Concurrently, the company has formally entered into a strategic partnership with the Chongqing Center for Disease Control and Prevention, marking the beginning of a new chapter in collaborative development between public health services and the biomedical industry.
This milestone acceptance of the mpox mRNA vaccine clinical trial application in China follows the vaccine's prior receipt of clinical trial authorization from the U.S. FDA. It represents the first mpox mRNA vaccine candidate in China to reach this stage. This achievement not only validates the company's product development capabilities but also serves as a strong affirmation of the potential of its mRNA technology platform. It signifies the company's solid capacity to contribute to global public health prevention and control efforts.
The consistent output of innovative results stems from the company's mRNA technology platform, which is led by a team of PhDs from both domestic and international backgrounds. The core strengths of this platform lie in its agile development process and potential for scalable production. Functioning as a "digital" platform, it enables rapid design and synthesis upon acquisition of a target sequence, facilitating quick iteration cycles. From a safety perspective, mRNA does not enter the cell nucleus, eliminating the risk of genomic integration. In terms of efficacy, through sequence optimization and advanced delivery systems, it can effectively activate both humoral and cellular immune responses. The company has already completed the technical groundwork for developing mRNA vaccines against single pathogens in the infectious disease arena and is rapidly expanding its efforts to include multi-pathogen combination vaccines and innovative mRNA-based cancer therapies. Furthermore, the company is actively leveraging AI technology to enhance the efficiency and quality of its mRNA platform.
A strategic cooperation signing ceremony was held in Chongqing, where both parties held discussions focusing on vaccine clinical research, scientific攻关 for infectious disease prevention and control, and laboratory testing. They reached significant consensus on promoting the development of innovative vaccines, jointly building technology platforms, and facilitating the transformation of scientific and technological achievements. Following the ceremony, attendees toured key research facilities at the Chongqing CDC, including its BSL-3 laboratory and pathogen strain repository.
As the institution that identified and managed mainland China's first imported mpox case, the Chongqing Center for Disease Control and Prevention possesses nationally leading technical expertise and practical experience in virus tracing, surveillance, early warning, and emergency response to infectious disease outbreaks. A foundation for this new partnership was previously established through a collaborative research project involving AB&B BIO-TECH-B, the First Affiliated Hospital of Chongqing Medical University, and the Chongqing Yuzhong District CDC, which studied the safety and immunogenicity of a quadrivalent influenza subunit vaccine in pregnant women. This new strategic alliance will significantly broaden the scope of cooperation, evolving from isolated projects to a systematic collaborative framework.
Moving forward, the partners will leverage their respective strengths in scientific research, clinical studies, and industrial translation. They plan to deepen cooperation on research projects in key areas such as the prevention, diagnosis, and treatment of infectious diseases. This will involve advancing the development and application of innovative vaccine technologies, strengthening biosafety laboratory infrastructure, and promoting the commercialization of cutting-edge technological achievements, thereby providing robust support for the high-quality development of public health initiatives.
Comments